Expanding the repertoire of low-molecular-weight pentafluorosulfanyl-substituted scaffolds

Accepted/In Press date: 22 February 2022

Published date: 5 April 2022

Additional Information: Funding Information: The authors acknowledge financial support from the ERDF (LabFact: InterReg V project 121), HEIF Covid‐19 Emergency Funds (University of Sussex), the Ewart Bequest Fund (University of Sussex), EPSRC (EP/P026990/1), Oxford COVID development fund, and Wellcome Trust for Institutional Strategic Support Fund (ISSF) (University of Sussex). This work was partly conducted as part of the Covid Moonshot Consortium (https://postera.ai/moonshot/) and we are grateful for their support. The authors also thank the Diamond Light Source for beam time (proposal mx19301) and the staff of beamlines I03 for assistance with crystal testing and data collection. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA‐DD grant no. 115766], Janssen, Merck KgaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, FAPDF, CAPES, CNPq, São Paulo Research Foundation‐FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. CJS thanks the Biotechnology and Biological Research Council, the Wellcome Trust, and Cancer Research UK. This research was funded in whole, or in part, by the Wellcome Trust [grant no. 106244/Z/14/Z]. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. T. R. M. thanks the BBSRC (BB/M011224/1) for her doctoral funding. N.L. received support from the Weizmann Institute Corona Response Fund. Funding Information: The authors acknowledge financial support from the ERDF (LabFact: InterReg V project 121), HEIF Covid-19 Emergency Funds (University of Sussex), the Ewart Bequest Fund (University of Sussex), EPSRC (EP/P026990/1), Oxford COVID development fund, and Wellcome Trust for Institutional Strategic Support Fund (ISSF) (University of Sussex). This work was partly conducted as part of the Covid Moonshot Consortium (https://postera.ai/moonshot/) and we are grateful for their support. The authors also thank the Diamond Light Source for beam time (proposal mx19301) and the staff of beamlines I03 for assistance with crystal testing and data collection. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KgaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, FAPDF, CAPES, CNPq, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. CJS thanks the Biotechnology and Biological Research Council, the Wellcome Trust, and Cancer Research UK. This research was funded in whole, or in part, by the Wellcome Trust [grant no. 106244/Z/14/Z]. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. T. R. M. thanks the BBSRC (BB/M011224/1) for her doctoral funding. N.L. received support from the Weizmann Institute Corona Response Fund. Publisher Copyright: © 2022 The Authors. ChemMedChem published by Wiley-VCH GmbH.

Keywords: COVID-19, SARS-COV-2 main protease (Mpro), DMARDs, SF group

Local EPrints ID: 455993

URI: http://eprints.soton.ac.uk/id/eprint/455993

DOI: doi:10.1002/cmdc.202100641

ISSN: 1860-7179

PURE UUID: ab331212-19c3-4a4a-9b0c-e09cbd3a5199

ORCID for Graham J. Tizzard: orcid.org/0000-0002-1577-5779

ORCID for Simon J. Coles: orcid.org/0000-0001-8414-9272

Date deposited: 11 Apr 2022 18:08

Last modified: 18 Mar 2024 02:54